Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation

Standard risk patients over 15 years old(except Ph+ ALL, AML t(8;21) and T-ALL) undergone unmanipulated blood and marrow transplantation following day 60 post-transplantation were randomized into treated group (with low dose IL-2 treatment) or controlled group (without any intervention post-transplantation). The end points were safety and clinical and immunologic response.Following time is 24 months. Primary Outcome Measures: \*To determine the feasibility and efficacy of administering an 6 course of subcutaneous IL-2 in this patient population. \[ Time Frame: 2 years \] Secondary Outcome Measures: \*To assess the immunologic impact of ultra-low dose subcutaneous IL-2 in patients after transplantation \[ Time Frame: 2 years \] Estimated Enrollment:360 Study Start Date:Jan 2012 Estimated Study Completion Date:Jan 2016 Intervention Details Description: \*Drug: Interleukin-2 Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks. Detailed Description: * Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. * Participants will be seen periodically while they are receiving IL-2. Physical exams and blood tests will be performed weekly for the first two weeks and then every other week until the completion of 6 course therapy. Eligibility Ages Eligible for Study:15 Years and older Genders Eligible for Study:Both Accepts Healthy Volunteers:No Criteria Inclusion Criteria: * Standard risk of Recipients of allogeneic stem cell transplantation with myeloablative conditioning regimens * Standard risk of Recipients: CR1 or CR 2 of AML/ALL before transplantation * Ph+ ALL，AML with t(8;21) and T-ALL were excepted * Patients were at least 60 days post-transplantation * Bone marrow monitoring was still Complete Remission (CR) and minor residual disease (MRD) was negative * 15 years of age or older * No serious infection Exclusion Criteria: * Exposure to any other clinical trials prior to enrollment * Active malignant disease relapse * Active, uncontrolled infection * Inability to comply with IL-2 treatment regimen